A Goldman Sachs economist has suggested that the US economy could experience accelerated growth with increased use of GLP-1 ...

The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...

In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...

HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...

CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...

Vaccine makers hit hardest as Robert F. Kennedy Jr. appointment to Department of Health raises concerns for US drug market.

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr.

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out drugs are emerging.

Boston Pharmaceuticals has linked its metabolic dysfunction-associated steatohepatitis (MASH) prospect to improved outcomes ...

Donald Trump’s nomination of vaccine-skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services is sending shockwaves throughout the broader pharma industry, beyond [vaccine ...

Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and ...

Polen Capital, an investment management company, released its “Polen Global Growth Strategy” third-quarter 2024 investor ...